Illumina announced it will add 50,000 whole genomes with paired proteomic data to the Alliance for Genomic Discovery (AGD) dataset, with pharmaceutical members GSK and Amgen leading the expansion. Proteomics will be generated by DeCode using Illumina’s Protein Prep assay; Regeneron Genetics Center will also join, expanding the AGD core to roughly 312,000 whole genomes. Illumina framed the move as an effort to integrate protein‑level measurements with genomic and longitudinal clinical data from electronic health records to accelerate human‑genetics‑driven drug target discovery. Leaders at NashBio and partner organizations emphasized that combined genomics‑proteomics datasets can sharpen causal inference and facilitate mechanistic follow‑up for targets emerging from large‑scale association studies. Proteomics paired with large genomic cohorts aims to bridge genetic signals to actionable biology by measuring the molecular consequences of variants at the protein level. For pharma R&D, richer multiomics cohorts could shorten target validation timelines and improve selection of drug modalities.